Biocon Biologics and Viatris Receive EC's Approval for Kixelle (biosimilar- insulin aspart) for Diabetes Mellitus
Shots:
- The EC approval follows CHMP’s positive recommendation for Kixelle to treat DM in adults- adolescents- and children aged ≥1yr. The biosimilar has been approved as a 100 units/ml solution for injection in vial & pre-filled pen presentations
- The EC’s CMA is valid in all EU Member States as well as in the EEA countries including Iceland- Liechtenstein- and Norway
- The approval will allow affordable access to a rapid-acting insulin analog for people with diabetes in the EU
Ref: Biocon | Image: Business Standard
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com